
Efficacy and Safety
Helping patients build new bone for more than 20 years
Teriparatide—the active ingredient in BONSITY—has been a mainstay anabolic therapy for osteoporosis since 2002.1
BONSITY helps three types of patients with osteoporosis build new bone2
Studies have demonstrated the efficacy of daily teriparatide injections in postmenopausal women with osteoporosis, in men with primary or hypogonadal osteoporosis, and in men and women with glucocorticoid-induced osteoporosis.
Select an indication to see the efficacy data:
BONSITY builds new bone in postmenopausal women with osteoporosis23
A clinical study evaluated the efficacy and safety of teriparatide injection (20 mcg daily; n=541) compared with placebo (n=544) in postmenopausal women. Patients were studied for a median of 19 months and a maximum of 24 months. In addition to study drug or placebo, patients took daily calcium and vitamin D supplements.

ap≤0.001 compared with placebo.
bp<0.05.
(n=541)
(p<0.001)
(n=544)
(n=541)
(p<0.05)
(n=544)
(n=541)
(p<0.05)
(n=544)
BONSITY increases bone mass in men with primary or hypogonadal osteoporosis23
A randomized study compared BMD changes in men treated with 20 mcg teriparatide daily via subcutaneous injection (n=151) compared with placebo (n=147) for a median of 10 months. Study participants also received daily vitamin D and calcium supplements.

(n=151)
(p<0.001)
(n=147)
(n=151)
(p<0.05)
(n=147)
(n=151)
(n=147)
BONSITY builds bone mass in men and women with corticosteroid-induced osteoporosis23
In an 18-month trial, men and women receiving sustained glucocorticoid therapy for chronic rheumatologic, respiratory, or other conditions were treated with 20 mcg teriparatide daily via subcutaneous injection (n=214). Patients also received daily calcium and vitamin D supplements. An active comparator was also assessed, but data from that treatment are not included here.

(n=214)
(p<0.001)
(n=214)
(p<0.001)
(n=214)
(p<0.001)
Safety and tolerability of BONSITY
In clinical studies of teriparatide, the most common adverse reactions in patients taking teriparatide vs placebo include2:
(n=691)
(n=691)
(n=691)
(n=691)
(n=691)
(n=691)
BONSITY is an affordable once-daily teriparatide injection
79% of Medicare Part D lives have access to BONSITY.3